RxDoctor Payments Data

Jessica Hanson, PA

Physician Assistant · Pasadena, TXNPI 1326386145

Payments from drug & device makers

$6,446in general payments, 2019–2025

Across 313 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$869
  • Inspire Medical Systems, Inc.$461
  • Neurocrine Biosciences, Inc.$407
  • Novartis$407
  • Harmony Biosciences LLC$332
  • Jazz Pharmaceuticals Inc.$323
  • plus $4K from 47 others

What the payments were for

  • Travel & lodging$3035%
  • Food & beverage$5,97293%
  • Education$1713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,446 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$49,393
Medicare patients
299
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$88,829
QuliptaAtogepant22$24,530
Aimovig AutoinjectorErenumab-Aooe24$17,628
Emgality PenGalcanezumab-Gnlm13$10,480
Memantine Hcl ErMemantine Hcl93$9,288
Ropinirole ErRopinirole Hcl58$6,508
Rasagiline Mesylate27$6,405
Divalproex Sodium ErDivalproex Sodium46$6,249
Memantine Hcl218$5,978
Gabapentin185$5,869
Lamotrigine ErLamotrigine13$3,971
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone12$3,670
Donepezil Hcl294$3,111
Levetiracetam68$2,418
Levetiracetam ErLevetiracetam25$2,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$407$88,82911 claims
AbbVieQulipta$869$24,53022 claims
Almatica Pharma LLCSertraline Hcl$27$48454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →